ImageneBio (NASDAQ:IMA) Shares Up 2.9% – Time to Buy?

Posted by Francis Steltz on Jul 30th, 2026

ImageneBio, Inc. (NASDAQ:IMA – Get Free Report)’s stock price traded up 2.9% on Tuesday . The stock traded as high as $5.76 and last traded at $5.76. 3,596 shares were traded during trading, a decline of 63% from the average daily volume of 9,627 shares. The stock had previously closed at $5.60.

Analyst Ratings Changes

IMA has been the subject of several recent research reports. Wedbush reissued an “underperform” rating on shares of ImageneBio in a research note on Monday, May 11th. Wall Street Zen lowered shares of ImageneBio from a “sell” rating to a “strong sell” rating in a research report on Sunday, May 17th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of ImageneBio in a research report on Monday, June 29th. One research analyst has rated the stock with a Strong Buy rating, one has given a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $30.00.

Read Our Latest Report on ImageneBio

ImageneBio Trading Up 6.1%

The stock has a market cap of $62.94 million, a price-to-earnings ratio of -1.02 and a beta of 0.73. The company has a fifty day simple moving average of $5.77 and a 200-day simple moving average of $6.01.

ImageneBio (NASDAQ:IMA – Get Free Report) last released its earnings results on Thursday, May 7th. The company reported ($0.95) earnings per share for the quarter, missing the consensus estimate of ($0.70) by ($0.25). As a group, analysts anticipate that ImageneBio, Inc. will post -3.66 earnings per share for the current year.

Institutional Trading of ImageneBio

Several large investors have recently added to or reduced their stakes in IMA. Rangeley Capital LLC boosted its position in shares of ImageneBio by 78.6% in the first quarter. Rangeley Capital LLC now owns 32,590 shares of the company’s stock worth $163,000 after buying an additional 14,346 shares during the period. Renaissance Technologies LLC raised its position in ImageneBio by 23.6% during the first quarter. Renaissance Technologies LLC now owns 81,696 shares of the company’s stock valued at $408,000 after buying an additional 15,600 shares during the period. BML Capital Management LLC raised its position in ImageneBio by 13.4% during the first quarter. BML Capital Management LLC now owns 200,730 shares of the company’s stock valued at $1,004,000 after buying an additional 23,704 shares during the period. Hsbc Holdings PLC purchased a new stake in ImageneBio in the 4th quarter worth about $233,000. Finally, Millennium Management LLC purchased a new stake in ImageneBio in the 4th quarter worth about $79,000. 75.00% of the stock is owned by institutional investors and hedge funds.

ImageneBio Company Profile

(Get Free Report)

ImageneBio, Inc, a clinical-stage biotechnology company, develops therapeutics for immunological and inflammatory diseases. Its lead product includes IMG-007, a non-depleting anti-OX40 mAb that has completed Phase 2a clinical trials for the treatment of atopic dermatitis and alopecia areata. The company was formerly known as Ikena Oncology, Inc and changed its name to ImageneBio, Inc in July 2025. ImageneBio, Inc is headquartered in San Diego, California.